Advertisement

Novartis wins approval for meningitis vaccine

Share this article

Photo: Copyright ® Novartis AG
18:16 CET+01:00
Swiss pharmaceutical group Novartis says it has won approval by the European Union's medicines agency for its Bexsero vaccine against meningitis B infections, the first broad coverage jab of its kind.

"Bexsero will be the first licensed broad coverage vaccine that can help protect all age groups against MenB (Meningococcal serogroup B) disease, including infants, the age group at the greatest risk of infection," Novartis said in a statement on Friday.

Current vaccines offer protection for several types of the disease that causes an inflammation of the membranes covering the brain and spinal cord, but not against MenB, which accounts for up to 90 percent of all cases of the disease in some European countries, the company said.

"MenB disease is easily misdiagnosed, can kill within 24 hours and may cause serious, life-long disabilities," Novartis said.

The highest rates of the disease occur the first year of life, peaking by seven months of age, the company said.

A final decision on whether the vaccine can be launched throughout the European Union and European Economic Area must be announced within three months by the European Commission, Novartis said.

Story continues below…

It said EU chiefs usually followed the recommendations of the Committee for Medicinal Products for Human Use (CHMP).

Approximately 1.2 million cases of invasive meningococcal disease are recorded worldwide, and 7,000 occur in Europe, according to the European Medicines Agency (EMA) which approved the vaccine.
  
Of the 13 meningococcal types, EMA said, in Europe group B is the most prevalent, with 3,406-4,819 cases reported annually between 2003 and 2007.

Share this article

Advertisement

From our sponsors

How to get British healthcare no matter where you are

Navigating the health care system in another country can be tough, and even when it all works out, sometimes you just miss the comfort of the system back home. But there's a solution.

Advertisement
Advertisement
Advertisement

Popular articles

Advertisement
Advertisement